Study of oral therapy for advanced lung cancer with egfr 19delins mutation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new oral therapy for people with advanced non-small cell lung cancer that has a specific EGFR mutation (19delins). It is for those who have not had treatment yet, and aims to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced non-small cell lung cancer (NSCLC) that cannot be removed by surgery or cured with other treatments.
- Your cancer must have a specific change in the EGFR gene called exon 19 deletion-insertion (19delins). This is usually found through a tumor or blood test.
- You should feel generally well (able to do most daily activities) and have a life expectancy of at least a year.
- You must not have had any prior treatment for your advanced lung cancer.
- You need to be able to take oral medication (swallow pills) and have regular follow-up tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
This trial tests whether giving the targeted drug icotinib along with chemotherapy before surgery can help people with a specific type of lung cancer (EGFR-mutated adenocarcinoma) that can be removed. The treatment aims to shrink the tumor and improve outcomes.
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
This trial tests different targeted therapies after surgery to lower the risk of early-stage lung cancer returning. It's designed for patients with high-risk features, and the treatment depends on the genetic changes in the tumor.
This trial studies a pill called icotinib, given after lung cancer surgery, to see if it helps prevent the cancer from returning in people with early-stage, EGFR-mutant non-small cell lung cancer. It is a real-world study, meaning it looks at how the treatment works in routine practice.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.